Changing Referral Characteristics of Patients with Autosomal Dominant Polycystic Kidney Disease
Overview
Affiliations
Objective: Autosomal dominant polycystic kidney disease is the most frequent life-threatening hereditary disease. The study objective was to assess whether the clinical characteristics of patients with autosomal dominant polycystic kidney disease who are referred to a major autosomal dominant polycystic kidney disease center have changed over time.
Methods: The clinical characteristics of patients with autosomal dominant polycystic kidney disease were compared between period A (1961-1990) and period B (1991-2011). The study took place at the Autosomal Dominant Polycystic Kidney Disease Center at the University of Colorado. A total of 837 patients referred with autosomal dominant polycystic kidney disease were included. Blood pressure control and renin-angiotensin-aldosterone system inhibition were instituted. Renal function, blood pressure, end-stage renal disease, and mortality were analyzed.
Results: The results in period B compared with period A demonstrated an earlier age of autosomal dominant polycystic kidney disease diagnosis (29 vs 35 years, P < .001), lower mean blood pressure (129/82 vs 142/91 mm Hg, P < .001), better estimated glomerular filtration rate (63.6 vs 44.6 mL/min, P < .001), and more therapy with angiotensin-converting enzyme inhibition (42.5% vs 13.6%, P < .001). Time from birth to end-stage renal disease (52.8 ± 0.6 vs 49.1 ± 0.6 years, P < .001) and birth to death (63.5 ± 1.5 years vs 57.2 ± 1.0 years, P < .001) was longer in period B compared with period A when adjusted for age at diagnosis, sex, and estimated glomerular filtration rate. The study was retrospective, which is a limitation.
Conclusions: In period B, there was significantly better blood pressure control, more renin-angiotensin-aldosterone system inhibition, better preservation of renal function, and a longer period from birth to end-stage renal disease and death.
A Systematic Review of Reported Outcomes in ADPKD Studies.
Jdiaa S, Husainat N, Mansour R, Kalot M, McGreal K, Chebib F Kidney Int Rep. 2022; 7(9):1964-1979.
PMID: 36090492 PMC: 9459055. DOI: 10.1016/j.ekir.2022.06.012.
Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease.
Hopp K, Catenacci V, Dwivedi N, Kline T, Wang W, You Z iScience. 2022; 25(1):103697.
PMID: 35059607 PMC: 8760407. DOI: 10.1016/j.isci.2021.103697.
Freise J, Tavakol M, Gao Y, Klein O, Lee B, Freise C Kidney Int Rep. 2019; 4(4):606-609.
PMID: 30993236 PMC: 6451113. DOI: 10.1016/j.ekir.2019.01.003.
Nowak K, You Z, Gitomer B, Brosnahan G, Torres V, Chapman A J Am Soc Nephrol. 2017; 29(2):571-578.
PMID: 29118087 PMC: 5791072. DOI: 10.1681/ASN.2017070819.
Fernando M, Dent H, McDonald S, Rangan G Popul Health Metr. 2017; 15(1):7.
PMID: 28212688 PMC: 5316166. DOI: 10.1186/s12963-017-0123-7.